~~<i id='87D74DEB81'><strike id='87D74DEB81'><tt id='87D74DEB81'><pre id='87D74DEB81'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：leisure time 2025-10-01 02:55:21 Page View：89968

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Private equity deals in Medicare Advantage declines
Next article： Medicare details structure of new drug price negotiation program

knowledge

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Biogen Alzheimer’s drug launch off to slow start

Illustration:AlexHogan/STAT;Photo:EisaiviaAPSevenmonthsafterUSdrugregulatorsfullyapprovedBiogen’stre

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

NIH nominee Bertagnolli will get October confirmation hearing

Dr.MonicaBertagnollispeaksduringavisitfromfirstladyJillBidentotheUniversityofCaliforniaSanFranciscoH